Vericiguat

Vericiguat, sold under the brand name Verquvo, is a medication used to reduce the risk of cardiovascular death and heart failure.[1][2][3] It is taken by mouth.[1][2][3]

Vericiguat
Clinical data
Trade namesVerquvo
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classSoluble guanylate cyclase activator
ATC code
Legal status
Legal status
Identifiers
  • methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard100.247.370
Chemical and physical data
FormulaC19H16F2N8O2
Molar mass426.388 g·mol−1
3D model (JSmol)
  • COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
  • InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)
  • Key:QZFHIXARHDBPBY-UHFFFAOYSA-N

Common side effects include low blood pressure and low red cell count (anemia).[2][3]

Vericiguat is a soluble guanylate cyclase (sGC) stimulator.[1] It was approved for medical use in the United States in January 2021,[2][4] and for use in the European Union in July 2021.[3]

Medical uses

Vericiguat is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.[1][2]

Adverse effects

Vericiguat causes harm to the unborn baby and should not be given to pregnant women.[2]

History

The U.S. Food and Drug Administration (FDA) approved vericiguat based on evidence from a clinical trial (NCT02861534) which consisted of 5,050 participants aged 23 to 98 years old with worsening heart failure.[2] The trial was conducted at 694 sites in 42 countries in Europe, Asia, North and South America.[2] The trial enrolled participants with symptoms of worsening heart failure.[2] Participants were randomly assigned to receive vericiguat or a placebo pill once a day.[2] Neither the participants nor the health care professionals knew if the participants were given vericiguat or placebo pill until after the trial was complete.[2]

Society and culture

On 20 May 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for vericiguat, intended for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.[5] The applicant for this medicinal product is Bayer AG. Vericiguat was approved for medical use in the European Union in July 2021.[3]

References
  1. "Verquvo- vericiguat tablet, film coated". DailyMed. Retrieved 9 February 2021.
  2. "Drug Trials Snapshot: Verquvo". U.S. Food and Drug Administration (FDA). 8 February 2021. Retrieved 8 February 2021. This article incorporates text from this source, which is in the public domain.
  3. "Verquvo EPAR". European Medicines Agency (EMA). 19 May 2021. Retrieved 14 September 2021.
  4. "Drug Approval Package: Verquvo". U.S. Food and Drug Administration (FDA). 17 February 2021. Retrieved 14 September 2021.
  5. "Verquvo: Pending EC decision". European Medicines Agency. 20 May 2021. Retrieved 23 May 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

Further reading
  • "Vericiguat". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02861534 for "A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.